Cell-cell fusion is the rate-limiting... [Cancer Genet Cytogenet. 2008] - PubMed

loading

Cell fusion, genetic cartography, and malignancy. [Lancet. 1976]
Cell fusion, genetic cartography, and malignancy.
Stanbridge EJ. Lancet. 1976 Sep 4; 1(7984):525.
Cell fusion: new mechanisms of plasticity in cancer? [Lancet Oncol. 2005]
Cell fusion: new mechanisms of plasticity in cancer?
Friedl P. Lancet Oncol. 2005 Dec; 6(12):916-8.
Review Aberrant expression of sialidase and cancer progression. [Proc Jpn Acad Ser B Phys Biol ...]
Review Aberrant expression of sialidase and cancer progression.
Miyagi T. Proc Jpn Acad Ser B Phys Biol Sci. 2008; 84(10):407-18.
Natural selection: The evolution of cancer. [Nature. 2008]
Natural selection: The evolution of cancer.
Goymer P. Nature. 2008 Aug 28; 454(7208):1046-8.
Review The role of the calcium-sensing receptor in the development and progression of cancer. [Endocr Rev. 2009]
Review The role of the calcium-sensing receptor in the development and progression of cancer.
Saidak Z, Mentaverri R, Brown EM. Endocr Rev. 2009 Apr; 30(2):178-95. Epub 2009 Feb 23.

A non-invasive technique for quantifying and isolating fused cells. [Cytotechnology. 2008]
A non-invasive technique for quantifying and isolating fused cells.
Hu L, Plafker K, Henthorn J, Ceresa BP. Cytotechnology. 2008 Nov; 58(3):113-8. Epub 2009 Feb 28.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Cell-cell fusion is the rate-limiting step in causation and progression of clini...
Cell-cell fusion is the rate-limiting step in causation and progression of clinically significant cancers.
Cancer Genet Cytogenet. 2008 Sep ;185(2):113.

PubMed
Tuberous sclerosis.
Tuberous sclerosis.
Lancet. 2008 Aug 23 ;372(9639):657-68.

PubMed
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in ...
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Lancet. 2008 Aug 23 ;372(9639):646-55.

PubMed
Time to pump iron: iron-deficiency-signaling mechanisms of higher plants.
Time to pump iron: iron-deficiency-signaling mechanisms of higher plants.
Curr Opin Plant Biol. 2008 Oct ;11(5):530-5. Epub 2008 Aug 21 .

PubMed
Discovery of a novel class of PPARdelta partial agonists.
Discovery of a novel class of PPARdelta partial agonists.
Bioorg Med Chem Lett. 2008 Sep 15 ;18(18):5018-22. Epub 2008 Aug 9 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed